abstract |
The invention concerns the substantially pure (1S, 2R) enantiomer of milnacipran hydrochloride for its use for treating patients suffering from psychiatric disorders, while reducing the risk of suicidal behaviour or ideation in said patients, and/or for limiting the risk of suicidal behaviour or ideation induced by the treatment with one or several SSRIs or other actual anti-depressants. |